A new ‘Botox‘ targeted specifically at men! Xeomin or Xeo-Men as they advertise is made by Merz Pharmaceuticals & is approved by the FDA for the treatment of moderate to severe frown lines between the eyebrows. FDA approval of Xeomin was based on the results of 2 clinical US trials and found it showed non-inferiority to Botox when used in the same doses. It concluded that Xeomin is a safe and effective treatment for those lines between the eyebrows. However, now that Xeomin is approved by the FDA, doctors can use it both on-label & off-label to treat the same facial lines treated by Botox and Dysport, including frown lines, crow’s feet and forehead wrinkles.
So far, worldwide, more than 84,000 people have been treated with Xeomin injections. The US is actually the 20th country to approve the new drug. There however is something unique about Xeomin that differs from Botox. Xeomin is the first one that does not need to be refrigerated before use, which may make distribution a lot easier & potentially cheaper than Botox/Dysport. Xeomin also has zero additives, just botulinum toxin type A. Basically that just means that there may be less risk of developing antibodies in response to foreign invaders. The effects of Xeomin occur within one week (Botox/Dysport can take up to 2 weeks to show up). If you are interested in this product, make sure you tell your healthcare provider what other injections you’ve had as Xeomin should not be used interchangeably with other botulinum products.
Why it’s targeted more towards men? We’re not quite sure. Maybe because of the natural similarities between Xeo-men and Xeomin – could be as simple as that. But both men and women are using this product for professional frown line treatment & of course other lines and wrinkles all over the face.
We took a photo of the brochure we picked up at our local skincare office & as you can see the results are promising.
Are you ready to ‘move up to the next level of skin treatment’?! If so, be sure to ask your healthcare provider. If you have questions regarding this relatively new botulinum product, leave a reply below.